Terns Pharmaceuticals Inc’s recent filing unveils that its Chief Medical Officer Kuriakose Emil unloaded Company’s shares for reported $7407.0 on Oct 01 ’25. In the deal valued at $7.85 per share,944 shares were sold. As a result of this transaction, Kuriakose Emil now holds 51,520 shares worth roughly $0.42 million.
Then, Kuriakose Emil sold 853 shares, generating $3,640 in total proceeds. Upon selling the shares at $4.27, the Chief Medical Officer now owns 52,464 shares.
Before that, Gengos Andrew bought 10,000 shares. Terns Pharmaceuticals Inc shares valued at $39,283 were divested by the Chief Financial Officer at a price of $3.93 per share. As a result of the transaction, Gengos Andrew now holds 25,000 shares, worth roughly $0.21 million.
Barclays initiated its Terns Pharmaceuticals Inc [TERN] rating to an Overweight in a research note published on September 17, 2025; the price target was $15. William Blair began covering TERN with “Mkt perform” recommendation on February 28, 2025. Oppenheimer started covering the stock on October 31, 2024. It rated TERN as “an Outperform”.
Price Performance Review of TERN
On Friday, Terns Pharmaceuticals Inc [NASDAQ:TERN] saw its stock jump 2.49% to $8.23. Over the last five days, the stock has gained 7.72%. Terns Pharmaceuticals Inc shares have risen nearly 1.60% since the year began. Nevertheless, the stocks have risen 48.56% over the past one year. While a 52-week high of $8.46 was reached on 10/03/25, a 52-week low of $1.87 was recorded on 04/07/25.
Levels Of Support And Resistance For TERN Stock
The 24-hour chart illustrates a support level at 8.05, which if violated will result in even more drops to 7.88. On the upside, there is a resistance level at 8.36. A further resistance level may holdings at 8.50.
How much short interest is there in Terns Pharmaceuticals Inc?
A steep rise in short interest was recorded in Terns Pharmaceuticals Inc stocks on 2025-09-15, growing by 1.19 million shares to a total of 8.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 7.12 million shares. There was a rise of 14.3%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 22, 2023 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
